



(DIPROPYLAMINO)-TETRAHYDRONAPHTHOFURANS: CENTRALLY ACTING SEROTONIN AGONISTS AND DOPAMINE AGONISTS-ANTAGONISTS


Peter Stjernlöf^{a*}, Chiu-Hong Lin^b, Clas Sonesson^a, Kjell Svensson^c and Martin W. Smith^d

^aMedicinal Chemistry Unit, Department of Pharmacology, Göteborg University, Medicinargatan 7, S-41390 Göteborg, SWEDEN. ^bStructural, Analytical and Medicinal Chemistry Research, ^cCNS Diseases Research and ^dDiscovery Technologies, Pharmacia & Upjohn Inc., Kalamazoo, MI 49001, U.S.A. © 1997 Elsevier Science Ltd.

Abstract. CNS-active aminotetralins containing phenolic moieties were transformed in a simple two-step procedure to the corresponding benzofurans. The compounds were tested in *in vitro* binding studies at serotonin 5-HT_{1A} and 5-HT₂ and dopamine D₂, D₃ and D₄ receptors. These studies revealed that the furan homologs showed overall lower affinities than the phenol counterparts. This was also reflected *in vivo* in biochemical studies. The benzofuran compounds retained most of the agonist/antagonist activities but with lower potency.

Phenolic aminotetralins and their corresponding methoxy derivatives have been widely used as pharmacological tools in CNS-research, in both the dopaminergic and serotonergic areas. 8-Hydroxy-2-(dipropyl)-aminotetralin (**1**, 8-OH-DPAT) is a very potent serotonin 5-HT_{1A} agonist and is the ligand of choice for binding experiments at the 5-HT_{1A} receptor.¹⁻⁴ The pyrrolidino fused compound *cis*-(3a*R*)-(-)-**2** has also been reported as a high affinity 5-HT_{1A} receptor agonist.⁵ Similarly 7-OH-DPAT (**3**) and 5-OH-DPAT (**4**) have been widely used in the dopamine area, the former lately as a dopamine D₃ agonist and the latter as a dopamine D₂ agonist.^{1,6-14} The 1-methylated 5-methoxy derivative (*cis*-1*S*,2*R*-(+)-**5**, UH232) is reported as a dopamine autoreceptor antagonist.^{15,16} This type of compounds, especially the phenolic, suffers from poor oral bioavailability.¹⁷⁻²²

Fig. 1




In a series of articles, it has been demonstrated that indolic aminotetralins and derivatives thereof, not only mimic the action of phenolic aminotetralins but also possess superior pharmacokinetic properties in terms of oral bioavailability.^{21,23,24} In this preliminary investigation, we have synthesized similar benzofuran isosteres to the mentioned hydroxy and methoxy compounds for comparison in terms of *in vitro* and *in vivo* assessment. There are several possible approaches to benzofurans. Since phenolic compounds were readily available, both "in house" and from fine chemicals suppliers, we sought a method for converting these phenolic compounds directly

Email: peter.stjernlof@pharm.gu.se


to their corresponding benzofurans. It has been reported that benzthiophenes and indoles can be produced from the corresponding thiols and anilines by alkylation with bromoacetaldehyde diethyl acetal followed by boron trifluoride diethyl etherate catalyzed cyclization in trifluoroacetic anhydride.²⁵ The authors found that in the case of benzofuran homologs only polymeric material was obtained. We tried a similar procedure and used after some initial experiments a more inert solvent for the cyclization step, dichloromethane. Several acidic catalysts were tested in the cyclization step but only boron trifluoride diethyl etherate resulted in desired products (Scheme 1, Table 1)²⁶. Included in the study is also α -naphthol, as a comparison starting material without an amino functionality.

Scheme 1.



In Fig. 2, the compounds synthesized by this method, are shown. The yields were almost quantitative in the first alkylation step. In the second step however, it seemed that also in this case amounts of the raw product were obtained as polymers as in ref.²⁵. This renders the method somewhat unpredictable in terms of expected yields (Table 1). A deeper synthetic-technical evaluation of the utility and yield optimization possibilities of this cyclization method is therefore desired. Notable is also that compound **3** yielded both compound **8** and its isomeric furan fused to the other side of the oxygen. The latter compound was detected but could not successfully be separated and isolated in its pure form (LC, HPLC). Yields were not improved significantly when the reaction was performed on α -naphthol, giving compound **11**.

Fig 2.

**Table 1.** Compounds synthesized.

Compound synthesized ^a	LC elute ^b	Recrystn. solvent ^c	m.p. (°C)	Isol. Yield (%) ^d
6 -HCl	A	A	215-218	11
<i>cis</i> -(3aR)-(-)- 7 -HCl	B	B	208-209	21
8 -HCl	C	A	240-243	13 (of 30 tot) ^f
9 -(free base)	C	-	oil	13
<i>cis</i> -1 <i>S</i> ,2 <i>R</i> -(+)- 10 (free base) ^g	D	-	oil	13
11	E	-	oil	30

^aSpectral data in Note 26. ^bA=CH₂Cl₂/*i*-PrOH (9:1), B=Hexane/Acetone (4:1), C=CH₂Cl₂/MeOH (19:1), D=CH₂Cl₂/MeOH (9:1), E=*iso*-octane/EtOAc (19:1). ^cA=MeOH/Et₂O, B=EtOAc/Hexane/MeOH(trace). ^dYield of purified product for the two steps. ^eHygroscopic. ^fYield in parenthesis include compound **8** and its isomeric furan ^gThe phenolic precursor was synthesised from UH232 (*cis*-1*S*,2*R*-(+)-**5**) by reflux in conc HBr for 3 hrs, evaporation and basic work-up.

The furan derivatives were tested *in vitro* for their ability to displace $^3\text{[H]}$ -8-OH-DPAT, $^3\text{[H]}$ -ketanserin, $^3\text{[H]}$ -U86170²⁷ and $^3\text{[H]}$ -spiperone from 5-HT_{1A}, 5-HT₂, D₂, D₃ and D₄ receptor sites respectively, expressed in cloned Chinese Hamster Ovarial (CHO) cells (Table 2). The compounds were also tested for *in vivo* agonist activity in serotonergic, dopaminergic and noradrenergic systems of reserpine pretreated rats (Table 3). Dopamine autoreceptor antagonist activity was assessed in non-pretreated rats (Table 4). In both *in vivo* methods the synthesis rate of neurotransmitter precursors (5-HTP and DOPA accumulation after decarboxylase inhibition by means of NSD1015) was used as indices of agonist/antagonist activity. Motor activity was recorded in an electronic motility meter. The benzofurans were compared with their corresponding phenols.

Table 2. *In vitro* binding affinities.

Compound	5-HT _{1A}	5-HT ₂	D ₂ K _i (nM) ^a	D ₃	D ₄
1	0.4±0.2	1614±493	86±8	259±80	>1515
<i>cis</i> -(3aR)-(-)- 2 ^d	0.2±0.1	1637±732	769±94	>4762	>4067
3	47±18	NT ^b	2.5±0.5	1.4±0.6	148±27
4	344±58	NT	0.7±0.05	4.4±0.3	NT
<i>cis</i> -1 <i>S</i> ,2 <i>R</i> -(+)- 5	168±11 ^g	NT	15±0.7 ^g	4.2±0.3 ^g	48±2 ^g
6	6.1±1.1	I	32±2	16.2±2	I
<i>cis</i> -(3aR)-(-)- 7	3.9±0.9	146±21	150±46	323±245	>4067
8	7.8±1.1	I	64±7	45±8	I
9	210±18	I	18±2	56±11	I
<i>cis</i> -1 <i>S</i> ,2 <i>R</i> -(+)- 10	120±18	70±7	46±2	27±6	55±7

^aK_i values followed by SEM. ^bNT=Not Tested. ^cI=Inactive (less than 50% inhibition at 1μM) ^dBinding values from ref.⁵. ^e[³H]-8-OH-DPAT-labelled 5-HT_{1A}-sites in bovine hippocampus. ^f[³H]-raclopride-labelled D₂-sites in rat striatum. ^gData from ref.²⁸

Table 3. *In vivo* effects on 5-HT and DA synthesis in rat brain as measured by 5-HTP and DOPA accumulation in reserpine pretreated animals.

Compound ^b	DOPA accumulation ^a			5-HTP-accumulation ^a		
	Limb. ED ₅₀ (μmol/kg) ^c	Stri. ED ₅₀ (μmol/kg) ^c	Hem.	Limb. ED ₅₀ (μmol/kg) ^c	Stri. ED ₅₀ (μmol/kg) ^c	Hem.
1 ^d	P ^e (45)	P(45)	P(45)	0.052	0.063	0.052
3 ^d	0.027	0.03	I ^f (11)	I(11)	I(11)	I(11)
4 ^d	0.011	0.009	I(13.5)	I(13.5)	I(13.5)	I(13.5)
6	P(50)	P(50)	I(50)	3.24 (5.48±0.36)	3.18 (5.49±0.34)	2.26 (5.64±0.32)
<i>cis</i> -(3aR)-(-)- 7	I(12.5)	P(12.5)	I(12.5)	0.41 (6.38±0.38)	0.40 (6.39±0.50)	0.66 (6.18±0.23)
8	4.47 (5.34±0.35)	13.05 (4.88±0.40)	I(50)	4.56 (5.34±0.21)	2.12 (5.67±0.70)	6.08 (5.22±0.82)
9	0.74	0.98	I(50)	I(50) (6.13±0.16)	I(50) (6.01±0.21)	I(50)

^alimb=limbic regions. stri=corpus striatum. hem=hemispheres. ^bCompound 2 has not been tested in these models. ^cED₅₀ values calculated as in ref.²³ ^dData from ref. 1. ^eP=Partial effects in the highest dose tested (Dose in parenthesis). ^fI=Inactive in the highest dose tested (dose in parenthesis).

Table 4. *In vivo* DA effects in non-pretreated rats. DA synthesis (DOPA accumulation) and locomotor activity

Compound	DOPA accumulation ^a (% of saline control) (50 μmol/kg)		Locomotor activity ^a (% of saline control) (50 μmol/kg)
	limbic regions	striatum	
<i>cis</i> -1 <i>S</i> ,2 <i>R</i> -(+)-5 ^b	245***	370***	70±13**
<i>cis</i> -1 <i>S</i> ,2 <i>R</i> -(+)-10	121±8 ^c	161±8***	107±11 ^c

^a ***Denotes $p < 0.001$, ** $p < 0.01$, * $p < 0.05$. ^b Data from ref 29. ^c Not significant.

In general, the biological responses for the benzofuran derivatives were comparable to the corresponding phenolic derivatives even though the potencies were lower. Also, for certain benzofurans, the selectivity was altered. Compound **6** retained some of the 5-HT_{1A} affinity of 8-OH-DPAT, **1** (10 times lower affinity) and was still quite selective *in vivo* for 5-HT responses, however, was less potent. In addition this compound **6** possessed some affinity for dopaminergic receptors. Compound *cis*-(3*aR*)-(-)-**7** was also a quite potent 5-HT_{1A} agonist which is reflected both *in vitro* and *in vivo* results. The dopaminergic activity of 5-OH-DPAT **4**, was retained although with lower potency and affinities in its corresponding benzofuran derivative **9**. The benzofuran derivative **8** of 7-OH-DPAT, **3**, showed mixed dopaminergic and serotonergic agonist effects which are more similar to its indole homolog (see refs. ^{21,24}) than to 7-OH-DPAT. Notable is that also compound *cis*-1*S*,2*R*-(+)-**10** retained some of the biochemical antagonist activity of its methoxy counterpart UH232 *cis*-1*S*,2*R*-(+)-**5**, see Table 4) as judged by elevated DOPA formation.

In summary, a convenient but not optimized synthetic method to prepare furans from phenolic compounds is reported.³⁰ The prepared furan analogs of the biologically active phenols, in general retained some of the activity of the phenolic compounds, although with lower potency.

Acknowledgements. The authors thank Prof. Arvid Carlsson for providing excellent working facilities and Maria Gullme, Kirsten Sønniksen, Arja Schedwin and Lena Wollter for skilful technical assistance and Susanne R. Haadsmas-Svensson for much administrative help. The financial support from The Upjohn Company, Kalamazoo, MI, U.S.A is gratefully acknowledged.

References and notes

- (1) Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G.; Hjorth, S.; Carlsson, A.; Lindberg, P.; Sanchez, D.; Wikström, H. *J. Med. Chem.* **1981**, *24*, 921-923.
- (2) Hjorth, S.; Carlsson, A.; Lindberg, P.; Sanchez, D.; Wikström, H.; Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G. *J. Neural Transmission* **1982**, *55*, 169-188.
- (3) Middlemiss, D. N.; Foxard, J. R. *Eur. J. Pharmacol.* **1983**, *90*, 151-153.
- (4) Gozlan, H.; El Mestkawy, S.; Pichat, L.; Glowinski, J.; Hamon, M. *Nature* **1983**, *305*, 140-142.
- (5) Lin, C. H.; Haadsmas-Svensson, S. R.; Lahti, R. A.; McCall, R. B.; Piercy, M. F.; Schreur, P. K. D.; Von Voightlander, P. F.; Smith, M. W.; Chidester, C. G. *J. Med. Chem.* **1993**, *36*, 1053-1068.
- (6) Hacksell, U.; Svensson, U.; Nilsson, L. G.; Hjorth, S.; Carlsson, A.; Wikström, H.; Lindberg, P.; Sanchez, D. *J. Med. Chem.* **1979**, *22*, 1469-1475.

- (7) McDermed, J. D.; McKenzie, G. M.; Phillips, A. P. *J. Med. Chem.* **1975**, *18*, 362-367.
- (8) McDermed, J. D.; McKenzie, G. M.; Freeman, H. S. *J. Med. Chem.* **1976**, *19*, 547-549.
- (9) Svensson, K.; Carlsson, A.; Waters, N. *J. Neural Transm. [GenSect]* **1994**, *95*, 71-74.
- (10) Feenstra, M.; Rollema, H.; Dijkstra, D.; Grol, C. J.; Horn, A. S.; Westerink, B. H. C. *Naunyn-Schmied. Arch. Pharmacol.* **1980**, *313*, 213-219.
- (11) Chumpradit, S.; Kung, M.-P.; Kung, H. F. *J. Med. Chem.* **1993**, *36*, 4308-4312.
- (12) Seiler, M. P.; Markstein, R. *Mol. Pharmacol.* **1984**, *26*, 452-457.
- (13) Beart, P. M.; Cook, C. J.; Cincotta, M.; deVries, D. J.; Tepper, P.; Dijkstra, D.; Hora, A. S. *Naunyn-Schmiedberg's Arch. Pharmacol.* **1987**, *336*, 487-493.
- (14) Tedesco, J. L.; Seeman, P.; McDermed, J. D. *Mol. Pharmacol.* **1979**, *16*, 369-381.
- (15) Johansson, A. M.; Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G.; Svensson, K.; Hjorth, S.; Clark, D.; Carlsson, A.; Sanchez, D.; Andersson, B.; Wikström, H. *J. Med. Chem.* **1985**, *28*, 1049-1053.
- (16) Svensson, K.; Johansson, A. M.; Magnusson, T.; Carlsson, A. *Naunyn-Schmiedberg's Arch. Pharmacol.* **1986**, *334*, 234-235.
- (17) Gabe, E. J.; LePage, Y.; Charland, J.; Lee, F. L. *J. Appl. Cryst.* **1989**, *22*,
- (18) Gerding, T. K.; Drenth, B. F. H.; de Zeeuw, R. A.; Tepper, P. G.; Horn, A. S. *Xenobiotica* **1990**, *20*, 525-536.
- (19) Gerding, T. K.; Drenth, B. F. H.; Roostenstein, H. J.; de Zeeuw, R. A.; Tepper, P. G.; Horn, A. S. *Xenobiotica* **1990**, *20*, 515-524.
- (20) Swart, P. J.; Jansman, E. G. A.; Drenth, B. F. H.; de Zeeuw, R. A.; Dijkstra, D.; Horn, A. S. *Pharmacol. Toxicol.* **1991**, *68*, 215-219.
- (21) Stjernlöf, P.; Gullme, M.; Elebring, T.; Anderson, B.; Wikström, H.; Lagerquist, S.; Svensson, K.; Ekman; Carlsson, A.; Sundell, S. *J. Med. Chem.* **1993**, *36*, 2059-2065.
- (22) Smith, D. A. *Eur. J. Drug. Metab. Pharmacokinet.* **1994**, *3*, 193-199.
- (23) Stjernlöf, P.; Elebring, T.; Nilsson, J.; Andersson, B.; Svensson, K.; Lagerkvist, S.; Ekman, A.; Carlsson, A.; Wikström, H. *J. Med. Chem.* **1994**, *37*, 3263-3273.
- (24) a) Stjernlöf, P.; Ennis, M. D.; Hansson, L. O.; Hoffman, R. L.; Ghazal, N. B.; Sundell, S.; Smith, M. W.; Svensson, K.; Carlsson, A.; Wikström, H. *Ibid.* **1995**, *38*, 2202-2216. b) Ennis, M. D.; Stjernlöf, P.; Hoffman, R. L.; Ghazal, N. B.; Smith, M. W.; Svensson, K.; Wikström, H. Haadsma-Svensson, S.R.; Lin, C-H. *Ibid.* **1995**, *38*, 2217-2230.
- (25) Bevis, M. J.; Forbes, E. J.; Naik, N. N.; Uff, B. C. *Tetrahedron* **1971**, *27*, 1253-1259.
- (26) A typical procedure was as follows: a mixture of the phenolic compound (1 eq) and sodium hydride (4 eq, 60% in mineral oil, washed with hexane and dried) in DMF (approx. 1M solution of phenol) was stirred at r. t. for 1 hr. Bromoacetaldehyde dimethylacetal was added and the mixture was stirred at 70 °C for 4-12 h, cooled and quenched with 15% NaOH. After drying, filtration and concentration of the organic phase, the resulting acetal (I, Scheme 1) was dissolved in HOAc and concentrated. The HOAc-salt was dissolved in CH₂Cl₂ and treated with approx. 4 eq BF₃-Et₂O and stirred for 24 h. The progress of the reaction was followed by GC (unidentified intermediates were observed). The mixture was treated with 15% NaOH. Additional extractions (CH₂Cl₂), followed by drying, filtration and concentration yielded a residue, which was purified on silica to give II (Scheme 1, Table 1). **Compound 6**: Dipropyl-(6,7,8,9-tetrahydronaphtho[1,2-*b*]furan-8-yl)amine. ¹H NMR (300 MHz, CDCl₃) δ 0.9 (t, 6H), 1.5 (s, 4H), 1.8

- (octet, 1H), 2.05 (br.d, 1H), 2.55 (t, 4H), 2.7-3.3 (m, 5H), 6.7 (d, J=2.2 Hz, 1H), 6.97 (d, J=8.0 Hz, 1H), 7.33.d (8.0, 1H), 7.57 (d, J=2.2 Hz, 1H); MS *m/e* 271 (M+, 30), 242 (100), 171 (75), 128 (15), 141 (13), 115 (12), C,H*,N. **Compound 7:** 8-Propyl-7,7a,8,9,10,10a-hexahydro-6H-1-oxa-8-aza-dicyclopenta[*a,h*] naphthalene. ¹H NMR (300 MHz, CDCl₃) δ 0.95 (t, 3H), 1.4-3.2 (m, 13H), 3.74 (? , J=8.6 Hz, 1H), 6.70 (d, J=2.2 Hz, 1H), 6.97 (d, J=7.9 Hz, 1H), 7.30 (d, J=7.9 Hz, 1H), 7.55 (d, J=2.2 Hz, 1H); MS *m/e* 255 (M+,), 226(100), 169 (6), 141 (6); [α]_D²⁰ -91.0° (c=0.9, Methanol, free base), C,H,N. **Compound 8:** Dipropyl-(6,7,8,9-tetrahydronaphtho[2,1-*b*]furan-8-yl)amine. ¹H NMR (300 MHz, CDCl₃) δ 0.9 (t, 6H), 1.5 (s, 4H), 1.7 (octet, 1H), 2.1 (br.d, 1H), 2.55 (t, 4H), 2.7-3.2 (m, 5H), 6.75 (dd, J=0.9, 2.2 Hz, 1H), 7.0 (d, J=8.6 Hz, 1H), 7.5.d (8.3, 1H), 7.57 (d, J=2.3 Hz, 1H); MS *m/e* 271 (M+, 11), 171 (100), 242 (57), 128 (23), 115 (17), 141 (15), C,H*,N. **Compound 9:** Di-*n*-propyl-(6,7,8,9-tetrahydronaphtho[1,2-*b*]furan-7-yl)-amine. ¹H NMR (200 MHz, CDCl₃) δ 0.90 (t, 6H), 1.50 (s, 4H), 1.70 (oct, 1H), 2.2 (br.d, 1H), 2.55 (t, 4H), 2.8-3.2 (m's, 4H), 3.3 (d of d, 1H), 6.70 (d, J=2.1 Hz, 1H), 6.98 (d, J=8.1 Hz, 1H), 7.34 (d, J=8.0 Hz, 1H), 7.56 (d, J=2.2 Hz, 1H); MS *m/e* 271 (M+, 9), 171 (100), 242 (45), 128 (26), 115 (18), 141 (18), 145 (15), HRMS. **Compound 10:** (6-Methyl-6,7,8,9-tetrahydronaphtho[1,2-*b*]furan-7-yl)-dipropyl-amine. ¹H NMR (300 MHz, CDCl₃) δ 0.9 (t, 6H), 1.2 (d, 3H), 1.5 (m, 4H), 1.9 (m, 1H), 2.55-2.75 (m, 4H), 2.8-3.1 (m, 3H), 3.25 (m, 2H), 6.72 (d, J=2.2 Hz, 1H), 7.0 (d, J=8.0 Hz, 1H), 7.4 (d, J=8.0 Hz, 1H), 7.6 (d, J=2.0 Hz, 1H); MS *m/e* 285 (M+, 36), 256 (100), 185 (96), 158 (36), 128 (16); [α]_D²⁰ +33.4° (c=1.0, Methanol, free base), HRMS. **Compound 11:** Naphtho[1,2-*b*]furan ¹H NMR (300 MHz, CDCl₃) δ 6.95 (d, J=1.5 Hz, 1H), 7.54 (t, J=8.1 Hz, 1H), 7.65 (t, J=8.1 Hz, 1H), 7.81 (d, J=2.2 Hz, 1H), 7.98 (d, J=8.1 Hz, 1H), 8.38 (d, J=8.1 Hz, 1H); MS (*m/e* 168 (M+, 100), 139 (62), 140 (26), 63 (14)).* Denotes that value deviates 0.5-0.6 %
- (27) Moon, M. W.; Morris, J. K.; Heier, R. F.; Hsi, R. S. P.; Manis, M. O.; Royer, M. E.; Walters, R. R.; Lawson, C. F.; Smith, M. W.; Lahti, R. A.; Piercey, M. F.; Sethy, V. H. *Drug Des. Discovery* **1993**, *9*, 313-322.
- (28) Haadsma-Svensson, S. R.; Smith, M. W.; Lin, C. H.; Duncan, N. J.; Sonesson, C.; Wikström, H.; Waters, N.; Carlsson, A.; Svensson, K. *Bioorg. & Med. Chem. Lett.* **1994**, *4*, 689-694.
- (29) Svensson, K.; Hjorth, S.; Clark, D.; Carlsson, A.; Wikström, H.; Andersson, B.; Sanchez, D.; Johansson, A. M.; Arvidsson, L.-E.; Hacksell, U.; Nilsson, J. L. G. *J. Neural Transmission* **1986**, *65*, 1-27.
- (30) During the course of this work a similar approach (using Amberlyst 15 as catalyst) for cyclization appeared in the literature: Knölker, H-J; Fröhner, W. *Tetrahedron Lett.* **1996**, *37*, 9183-9186. By following that procedure we could prepare and isolate compound **11** from α-naphthol in 48% yield, whereas the phenol **3** yielded no product (**8ab**). Although very promising, this method needs to be modified to suit phenolic compounds having an amino moiety.

(Received in Belgium 19 June 1997; accepted 30 September 1997)